Apexigen Announces New Collaboration with UCSF

Apexigen today announced the initiation of patient enrollment in Phase 2 clinical trial in collaboration with the University of California San Francisco (UCSF). This trial is designed to evaluate Apexigen’s CD40 agonistic antibody, APX005M, in combination with multimodal treatment (chemotherapy and radiation therapy) in patients with resectable esophageal and gastroesophageal junction cancers.